Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Rating of "Hold" by Brokerages
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Rating of "Hold" by Brokerages
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) has been given an average recommendation of "Hold" by the twelve analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.90.
据MarketBeat报道,纳斯达克(Deciphera PharmPharmticals,Inc.)(股票代码:DCPH-GET Rating)目前负责该股的12位分析师给予该公司“持有”的平均建议。两名研究分析师对该股的评级为卖出,四名分析师对该公司的评级为持有,五名分析师对该公司的评级为买入。在过去一年发布该股报告的分析师中,平均一年目标价为17.90美元。
Several research analysts recently commented on DCPH shares. Piper Sandler raised their price target on shares of Deciphera Pharmaceuticals from $13.00 to $18.00 in a research note on Sunday, September 11th. HC Wainwright increased their target price on shares of Deciphera Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, September 12th. SVB Leerink raised their price target on shares of Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. JMP Securities upgraded shares of Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 target price for the company in a research note on Friday, August 5th. Finally, Cowen began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, August 29th. They issued an "outperform" rating and a $25.00 target price for the company.
几位研究分析师最近对DCPH的股票发表了评论。派珀·桑德勒在9月11日周日的一份研究报告中将Deciphera PharmPharmticals的目标价从13.00美元上调至18.00美元。在9月12日(星期一)的一份报告中,HC Wainwright将Deciphera PharmPharmticals的股票目标价从20.00美元上调至25.00美元,并给予该股“买入”评级。SVB Leerink在9月12日周一的一份报告中将Deciphera PharmPharmticals的股票目标价从21.00美元上调至25.00美元,并给予该公司“跑赢大盘”的评级。JMP Securities在8月5日(周五)的一份研究报告中将Deciphera PharmPharmticals的股票评级从“市场表现”上调至“表现优于大盘”,并为该公司设定了2300美元的目标价。最后,考恩在8月29日星期一的一份研究报告中开始报道Deciphera制药公司的股票。他们对该公司的评级为“跑赢大盘”,目标价为25.00美元。
Deciphera Pharmaceuticals Stock Performance
Deciphera制药类股表现
Shares of NASDAQ:DCPH opened at $18.10 on Friday. The firm has a fifty day moving average price of $15.97 and a 200 day moving average price of $12.63. Deciphera Pharmaceuticals has a fifty-two week low of $6.51 and a fifty-two week high of $20.88. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -4.23 and a beta of 1.00.
上周五,纳斯达克的股价开盘报18.10美元。该公司的50日移动平均价为15.97美元,200日移动平均价为12.63美元。Deciphera PharmPharmticals的股价为52周低点6.51美元,52周高点为20.88美元。该公司市值为12.1亿美元,市盈率为-4.23倍,贝塔系数为1.00。
Institutional Inflows and Outflows
机构资金流入和流出
Several institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its holdings in Deciphera Pharmaceuticals by 2.4% in the fourth quarter. Northern Trust Corp now owns 410,700 shares of the company's stock valued at $4,013,000 after purchasing an additional 9,740 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Deciphera Pharmaceuticals by 36.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 297,545 shares of the company's stock worth $2,907,000 after acquiring an additional 79,192 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Deciphera Pharmaceuticals by 29.5% in the fourth quarter. BNP Paribas Arbitrage SA now owns 20,140 shares of the company's stock worth $197,000 after acquiring an additional 4,588 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in Deciphera Pharmaceuticals in the fourth quarter worth $373,000. Finally, Goldman Sachs Group Inc. raised its position in Deciphera Pharmaceuticals by 739.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company's stock worth $35,519,000 after acquiring an additional 3,202,527 shares in the last quarter. Institutional investors and hedge funds own 72.29% of the company's stock.
几家机构投资者和对冲基金最近调整了对该公司的持股。北方信托公司在第四季度增持了Deciphera PharmPharmticals 2.4%的股份。Northern Trust Corp目前持有410,700股该公司股票,价值4,013,000美元,此前该公司在上个季度又购买了9,740股。Dimension Fund Advisors LP在第四季度将其在Deciphera PharmPharmticals的持仓提高了36.3%。Dimension Fund Advisors LP在上个季度增持了79,192股后,现在拥有297,545股该公司的股票,价值290.7万美元。法国巴黎银行套利SA在第四季度将其在Deciphera PharmPharmticals的头寸提高了29.5%。法国巴黎银行套利公司现在拥有20,140股该公司股票,价值19.7万美元,上个季度又收购了4,588股。Ensign Peak Advisors Inc.在第四季度购买了Deciphera制药公司的一个新头寸,价值37.3万美元。最后,高盛股份有限公司在第四季度将其在Deciphera PharmPharmticals的持仓提高了739.6%。高盛股份有限公司在上个季度增持了3,202,527股后,目前持有该公司3,635,510股股票,价值35,519,000美元。机构投资者和对冲基金持有该公司72.29%的股票。
About Deciphera Pharmaceuticals
关于Deciphera制药公司
(Get Rating)
(获取评级)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
生物制药公司Deciphera PharmPharmticals,Inc.通过解决美国和国际上限制对现有癌症疗法反应的速度和持久性的关键耐药机制,开发改善癌症患者生命的药物。它的主要候选药物是用于治疗胃肠道间质瘤(GIST)的QINLOCK,以及用于治疗二线GIST的3期试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于Deciphera制药的研究报告(DCPH)
- MarketBeat:回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性?
- 好市多盈利后价格疲软是买入的好时机吗?
- 需要关注的2只半导体类股走势逆转
- CrowdStrike是否会从增加每股收益指引中获得提振?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Deciphera PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Deciphera制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。